176 related articles for article (PubMed ID: 34100956)
1. [Side effects of immune checkpoint inhibitor treatment of urological tumors].
Grimm MO; Gottschlich T; Ali N; Foller S; Leucht K
Urologe A; 2021 Jun; 60(6):803-815. PubMed ID: 34100956
[TBL] [Abstract][Full Text] [Related]
2. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
Grimm MO; Bex A; De Santis M; Ljungberg B; Catto JWF; Rouprêt M; Hussain SA; Bellmunt J; Powles T; Wirth M; Van Poppel H
Eur Urol; 2019 Sep; 76(3):368-380. PubMed ID: 31235192
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
4. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R
Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302
[TBL] [Abstract][Full Text] [Related]
5. Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma.
Leucht K; Ali N; Foller S; Grimm MO
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139530
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
7. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors.
Kartolo A; Yeung C; Moffat GT; Hanna L; Hopman W; Baetz T
Immunotherapy; 2022 Jan; 14(1):23-30. PubMed ID: 34758641
[No Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature.
Bimbatti D; Maruzzo M; Pierantoni F; Diminutto A; Dionese M; Deppieri FM; Lai E; Zagonel V; Basso U
Crit Rev Oncol Hematol; 2022 Feb; 170():103579. PubMed ID: 35007699
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Investigation of Immune Checkpoint Inhibitor-Associated Kidney Injury in Patients with Urologic Cancers].
Kozen N; Tanaka T; Shindo T; Hashimoto K; Kobayashi K; Masumori N
Hinyokika Kiyo; 2022 Jul; 68(7):211-215. PubMed ID: 35924703
[TBL] [Abstract][Full Text] [Related]
11. [Systemic immune checkpoint inhibition : A promising treatment for urological tumors?].
Roos FC; Becker C; Stope MB; Tsaur I;
Urologe A; 2018 May; 57(5):583-590. PubMed ID: 29569115
[TBL] [Abstract][Full Text] [Related]
12. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
Kuusk T; Abu-Ghanem Y; Mumtaz F; Powles T; Bex A
Curr Opin Urol; 2021 May; 31(3):262-269. PubMed ID: 33742979
[TBL] [Abstract][Full Text] [Related]
13. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
[TBL] [Abstract][Full Text] [Related]
14. Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma.
Pourmir I; Noel J; Simonaggio A; Oudard S; Vano YA
World J Urol; 2021 May; 39(5):1377-1385. PubMed ID: 33386948
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
Hirsch L; Flippot R; Escudier B; Albiges L
Drugs; 2020 Aug; 80(12):1169-1181. PubMed ID: 32601914
[TBL] [Abstract][Full Text] [Related]
16. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
Grünwald V; Voss MH; Rini BI; Powles T; Albiges L; Giles RH; Jonasch E
Br J Cancer; 2020 Sep; 123(6):898-904. PubMed ID: 32587360
[TBL] [Abstract][Full Text] [Related]
17. [Immunooncology in Urologic Cancers: Current Status].
Grimm MO
Aktuelle Urol; 2016 Sep; 47(5):374-7. PubMed ID: 27680188
[TBL] [Abstract][Full Text] [Related]
18. Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments.
Schmidt AL; Siefker-Radtke A; McConkey D; McGregor B
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32379987
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Therapy for Urothelial and Renal Cell Carcinoma.
Patel HD; Kates M; Allaf ME
Eur Urol Focus; 2020 Jan; 6(1):3-6. PubMed ID: 31031041
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
